Condition 1: Lymphedema is the accumulation of lymphatic fluid in the extravascular space resulted from dysfunction of lymphatic drainage because of mostly structural damage in lymphatic vessels. Various etiology of lymphedema is consist of primary and genetic malfunctions presenting the disease congenitally, over the first year after birth, up to 35 years or after this age and cancers and their treatment methods, traumas and other causes for example filariasis can cause the secondary lymphedema
Conditions
Interventions
Intervention group: a single group of 10 patients with primary lower extremity(ies) lymphedema, with no exclusion criteria, will receive 10mcg/kg/day of G-CSF for 3-5 days to recruit more stem cells f
Treatment - Other
Sponsors
Hematology,Oncology and Stem Cell Transplantation Research Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: primary lower extremities lymphedema (stage < III)
Exclusion criteria
Exclusion criteria: Uncontrolled hypertension Diabetes Sever heart failure (EF<30 %) Coronary arterial disease Chronic renal disease History of any malignancies over the last 10 years History of chemo/radiotherapy in the last 10 years Organ transplantations in the last 10 years Active infection of the lower extremities
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Circumference of the lymphedematous lower extremity in specific distances of the limb length. Timepoint: Before intervention and then monthly up to 9 months. Method of measurement: Tape measuring.;Volume of the Circumference of the lymphedematous lower extremity. Timepoint: Before intervention and then monthly up to 9 months. Method of measurement: Volume of truncated cone formula. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life. Timepoint: Before intervention and end of the follow up time (9 months after intervention). Method of measurement: WHO QOL questionnaire (SF 26).;Lymphoscintigraphic Transport Index (TI). Timepoint: Before intervention and end of the follow up time (9 months after intervention). Method of measurement: Report of lymphoscintigraphy by the expert nuclear medicine specialist.;Average number of subcutaneous lymphatic vessels of the lower extremities. Timepoint: Before intervention and end of the follow up time (9 months after intervention). Method of measurement: Histopathologic investigation and immunohistochemistery (IHC) staining by the expert pathologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBehnam Molavi
Department of Vascular Surgery, Shariati Hospital
Outcome results
None listed